Long-term pharmacotherapy of obesity 2000 - A review of efficacy and safety

被引:117
作者
Glazer, G [1 ]
机构
[1] Univ Rochester, Sch Med & Dent, Rochester, NY USA
关键词
D O I
10.1001/archinte.161.15.1814
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To clarify the efficacy of antiobesity drugs, this article reviews all long-term (greater than or equal to 36 weeks), placebo-controlled trials of obesity pharmacotherapy published since 1960. Since fears of anorexiant-induced heart valve damage preclude many physicians and patients from even considering antiobesity drugs, this area is also reviewed in-depth. Electronic database and manual bibliography search was used to identify all relevant publications. While existing studies are too few and heterogeneous to warrant meta-analysis, their review does provide evidence highly relevant to the safety and efficacy of available anorexiants. Weight loss attributable to obesity pharmacotherapy (ie, in excess of placebo) in trials lasting 36 to 52 weeks was 8.1% or 7.9 kg for those receiving phentermine resin, 5.0% or 4.3 kg for those receiving sibutramine hydrochloride, 3.4% or 3.4 kg for those receiving orlistat, and -1.5% or -1.5 kg for those receiving diethylpropion hydrochloride. Physiologic, pathologic, and epidemiological studies strongly support that anorexiant-induced valvulopathy is attributable to specific serotonergic properties of the fenfluramines that are not present with available weight loss drugs.
引用
收藏
页码:1814 / 1824
页数:11
相关论文
共 115 条
[11]   Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months [J].
Burger, AJ ;
Sherman, HB ;
Charlamb, MJ ;
Kim, J ;
Asinas, LA ;
Flickner, SR ;
Blackburn, GL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (04) :1153-1158
[12]   Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment [J].
Cannistra, LB ;
Cannistra, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (11) :771-771
[13]  
Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1061
[14]  
CHIASSON JL, 1989, DIABETES S2, V38, P603
[15]   Safe and effective management of the obese patient [J].
Collazo-Clavell, ML .
MAYO CLINIC PROCEEDINGS, 1999, 74 (12) :1255-1260
[16]   Valvular heart disease associated with fenfluramine-phentermine [J].
Connolly, HM ;
Crary, JL ;
McGoon, MD ;
Hensrud, DD ;
Edwards, BS ;
Edwards, WD ;
Schaff, HV .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588
[17]   Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability [J].
Curzon, G ;
Gibson, EL ;
Oluyomi, AO .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (01) :21-25
[18]   Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial [J].
Davidson, MH ;
Hauptman, J ;
DiGirolamo, M ;
Foreyt, JP ;
Halsted, CH ;
Heber, D ;
Heimburger, DC ;
Lucas, CP ;
Robbins, DC ;
Chung, J ;
Heymsfield, SB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03) :235-242
[19]   Dexfenfluramine - An updated review of its therapeutic use in the management of obesity [J].
Davis, R ;
Faulds, D .
DRUGS, 1996, 52 (05) :696-724
[20]  
DERAMOS E C, 1964, Br J Clin Pract, V18, P210